INO Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

$8.90  -0.20 (-2.20%)
As of 06/14/2021 15:59:50 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/21/2001
Outstanding shares:  209,399,260
Average volume:  5,889,629
Market cap:   $1,916,003,229
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45773H201
ISIN:        US45773H2013
Sedol:      BN5H5K1
Valuation   (See tab for details)
PE ratio:   -10.12
PB ratio:   3.28
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy